CompanyTGTXNasdaqNew York, NY

TG Therapeutics, Inc.

TG Therapeutics is a commercial-stage biotechnology company developing B-cell therapies.

Stories only

SEC EDGAR ClinicalTrials.gov briumvi.com

424B3Sep 11Latest SEC filing

Aug 3Latest story

August 2026

TG Therapeutics posts Q2 2026 results, raises BRIUMVI revenue guidance

Aug 3Quarterly updateTG Therapeutics, Inc.ublituximab

July 2026

TG Therapeutics registers two Phase 2 ublituximab trials, in schizophrenia and myasthenia gravis

Jul 2Weekly roundup, 2 itemsTG Therapeutics, Inc.ublituximab

Pipeline by stage

Phase 3 primary completions, next 6 months

Oct 2026ublituximabrelapsing multiple sclerosis · NCT07211633

Jan 2027ublituximabrelapsing multiple sclerosis · NCT05877963

Details

Headquarters: New York, NY
Incorporated: Delaware
Industry: Pharmaceutical Preparations
Formerly: MANHATTAN PHARMACEUTICALS INC (to 2012); ATLANTIC TECHNOLOGY VENTURES INC (to 2003); ATLANTIC PHARMACEUTICALS INC (to 2000)
Also known as: ATLANTIC PHARMACEUTICALS INC, ATLANTIC TECHNOLOGY VENTURES INC, MANHATTAN PHARMACEUTICALS INC, TGTX

How the company describes itself

TG Therapeutics is a commercial-stage biotechnology company developing B-cell therapies. It markets BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the FDA for relapsing forms of multiple sclerosis in adults. source